Abdominal candidiasis is a hidden reservoir of echinocandin resistance

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7601-7605

  Shields, Ryan K ^a,b   Nguyen, M Hong ^a,b   Press, Ellen G ^a   Clancya, Cornelius J ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE; ANTIFUNGAL AGENT;

ABDOMINAL ABSCESS; ADULT; ANTIFUNGAL RESISTANCE; ARTICLE; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDEMIA; CHOLANGITIS; CLINICAL ARTICLE; DRUG TREATMENT FAILURE; FEMALE; FUNGUS ISOLATION; GASTROINTESTINAL CANDIDIASIS; GASTROINTESTINAL SURGERY; HUMAN; MALE; MULTIDRUG RESISTANCE; PERITONITIS; AGED; CANDIDIASIS; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; SURVIVAL;

ABDOMINAL ABSCESS; ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; PERITONITIS; SURVIVAL ANALYSIS;

EID: 84912077211     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04134-14     Document Type: Article

References (19)

1. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, Pappas PG, Kullberg BJ. 2012. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin. Infect. Dis. 54:1110-1122. http://dx.doi.org/10.1093/cid/cis021.
2. Shields RK, Nguyen MH, Press EG, Kwa AL, Cheng S, Du C, Clancy CJ. 2012. The presence of an FKS mutation rather thanMICis an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob. Agents Chemother. 56:4862-4869. http://dx.doi.org/10.1128/AAC.00027-12.
3. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56:1724-1732. http://dx.doi.org/10 .1093/cid/cit136.
4. Beyda ND, John J, Kilic A, Alam MJ, Lasco TM, Garey KW. 2014. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin. Infect. Dis. 59:819-825. http://dx.doi.org/10.1093/cid /ciu407.
5. Carneiro HA, Mavrakis A, Mylonakis E. 2011. Candida peritonitis: an update on the latest research and treatments. World J. Surg. 35:2650-2659. http://dx.doi.org/10.1007/s00268-011-1305-2.
6. Eschenauer GA, Nguyen MH, Shoham S, Vazquez JA, Morris AJ, Pasculle WA, Kubin CJ, Klinker KP, Carver PL, Hanson KE, Chen S, Lam SW, Potoski BA, Clarke LG, Shields RK, Clancy CJ. 2014. Realworld experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Antimicrob. Agents Chemother. 58:1897-1906. http://dx.doi.org/10.1128/AAC.02163-13.
7. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A, Fuller J, Gaustad P, Gonzalez GM, Guarro J, Lass-Florl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SR, St-Germain G, Szeszs MW, Turnidge J. 2013. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob. Agents Chemother. 57:5836-5842. http://dx.doi.org/10 .1128/AAC.01519-13.
8. Shields RK, Nguyen MH, Press EG, Updike CA, Clancy CJ. 2013. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob. Agents Chemother. 57:3528-3535. http://dx.doi.org/10 .1128/AAC.00136-13.
9. Shields RK, Nguyen MH, Press EG, Updike CL, Clancy CJ. 2013. Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata and echinocandin resistance. Antimicrob. Agents Chemother. 57:6361-6365. http://dx .doi.org/10.1128/AAC.01451-13.
10. th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18: 268-281. http://dx.doi.org/10.1111/j.1469-0691.2011.03570.x.
12. Clancy CJ, Staley B, Nguyen MH. 2006. In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole. Antimicrob. Agents Chemother. 50:3496-3498. http://dx.doi.org/10.1128/AAC.00741-06.
13. Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, Walsh TJ, Maertens J, Patterson TF, Perfect JR, Dupont B, Wingard JR, Calandra T, Kauffman CA, Graybill JR, Baden LR, Pappas PG, Bennett JE, Kontoyiannis DP, Cordonnier C, Viviani MA, Bille J, Almyroudis NG, Wheat LJ, Graninger W, Bow EJ, Holland SM, Kullberg BJ, Dismukes WE, De Pauw BE. 2008. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin. Infect. Dis. 47:674-683. http://dx.doi.org/10.1086/590566.
14. Clancy CJ, Nguyen MH. 2014. Undiagnosed invasive candidiasis: incorporating non-culture diagnostics into rational prophylactic and preemptive antifungal strategies. Expert Rev. Anti Infect. Ther. 12:731-734. http: //dx.doi.org/10.1586/14787210.2014.919853.
15. Cheng S, Clancy CJ, Hartman DJ, Hao B, Nguyen MH. 2014. Candida glabrata intra-abdominal candidiasis is characterized by persistence within the peritoneal cavity and abscesses. Infect. Immun. 82:3015-3022. http://dx.doi.org/10.1128/IAI.00062-14.
16. Goicoechea M, Fierer J, Johns S. 2004. Treatment of candidal cholangitis with caspofungin therapy in a patient with a liver transplant: documentation of biliary excretion of caspofungin. Clin. Infect. Dis. 38:1040-1041. http://dx.doi.org/10.1086/382082.
17. Yamada N, Kumada K, Kishino S, Mochizuki N, Ohno K, Ogura S. 2011. Distribution of micafungin in the tissue fluids of patients with invasive fungal infections. J. Infect. Chemother. 17:731-734. http://dx.doi.org /10.1007/s10156-011-0240-3.
18. Sandhu P, Xu X, Bondiskey PJ, Balani SK, Morris ML, Tang YS, Miller AR, Pearson PG. 2004. Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob. Agents Chemother. 48:1272-1280. http://dx.doi.org/10.1128/AAC.48.4.1272-1280 .2004.
19. Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. 2005. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob. Agents Chemother. 49:5058-5068. http: //dx.doi.org/10.1128/AAC.49.12.5058-5068.2005.